This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anastrozole in Patients With Pulmonary Arterial Hypertension (AIPH)

This study has been completed.
Information provided by (Responsible Party):
University of Pennsylvania Identifier:
First received: February 29, 2012
Last updated: September 20, 2016
Last verified: September 2016
The main purpose of this clinical trial is to study the safety and efficacy of anastrozole in adults diagnosed with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated. The study will also evaluate if anastrozole effects estradiol (E2) hormone levels, a sex hormone, and improves the function of the lower right chamber of the heart (right ventricle).

Condition Intervention Phase
Pulmonary Arterial Hypertension Drug: Anastrozole Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Plasma Estradiol (E2) Level [ Time Frame: Baseline, 3 months ]
  • Tricuspid Annular Plane Systolic Excursion (TAPSE) [ Time Frame: Baseline, 3 months ]

Secondary Outcome Measures:
  • Six Minute Walk Distance [ Time Frame: Baseline, 3 months ]

Enrollment: 18
Study Start Date: October 2012
Study Completion Date: September 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anastrozole
1 mg tablet by mouth once daily for 3 months
Drug: Anastrozole
1 mg tablet to be taken 1 time daily
Other Name: Arimidex
Placebo Comparator: Placebo
Placebo tablet by mouth once daily for 3 months
Drug: Placebo
1 mg tablet to be taken 1 time daily
Other Name: Sugar pill manufactured to mimic Anastrozole 1 mg tablet


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Previous documentation of mean pulmonary artery pressure > 25 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) < 16 mm Hg and PVR > 3 WU at any time before study entry.
  • Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection.
  • Most recent pulmonary function tests with FEV1/FVC >50% AND either a) total lung capacity > 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest
  • Ability to perform six minute walk testing without limitations in musculoskeletal function or coordination.
  • If female, post-menopausal state, defined as:
  • > 50 years old AND
  • a) have not menstruated during the preceding 12 months OR
  • b) have follicle-stimulating hormone (FSH) levels (> 40 IU/L) OR
  • < 50 years and FSH (> 40 IU/L) OR
  • having had a bilateral oophorectomy
  • Informed consent

Exclusion Criteria:

  • Treatment with estrogen or anti-hormone therapy (tamoxifen, fulvestrant, etc.)
  • WHO Class IV functional status
  • History of breast cancer
  • Clinically significant untreated sleep apnea
  • Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on echocardiography
  • Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors) within three months of enrollment; the dose must be stable for at least 3 months prior to Baseline Visit
  • Hormone therapy
  • Hospitalized or acutely ill
  • Renal failure (creatinine > 2.0)
  • Child-Pugh Class C cirrhosis
  • Current or recent (< 6 months) chronic heavy alcohol consumption
  • Current use of another investigational drug (non-FDA approved) for PAH
  • Enrollment in a clinical trial within one month of screening
  • Age < 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01545336

United States, Pennsylvania
University of Pennsylvania - Penn Presbyterian
Philadelphia, Pennsylvania, United States, 19104
University of Pennsylvania - Perelman Center
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Brown University - Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: Steven M Kawut, MD, MS University of Pennsylvania
  More Information

Responsible Party: University of Pennsylvania Identifier: NCT01545336     History of Changes
Other Study ID Numbers: 815035
Study First Received: February 29, 2012
Results First Received: June 29, 2016
Last Updated: September 20, 2016

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on August 22, 2017